Back to today’s briefing

Story perspectives

FDA Limits Obesity Drug Access Amid Safety Concerns

9/30/2025

34 4

Summary

Story summary

FDA guidelines restrict semaglutide and tirzepatide to individuals with a BMI of 30+ or 27+ with health risks.
Experts Judith Korner and Sarah Adler say obesity is a chronic disease requiring treatment.
Online sales of these drugs raise safety concerns due to lack of regulation.
Weight-loss interest stems from societal pressures around food; taste changes may occur, with reduced intake.

1 of 1

Story summary

FDA guidelines restrict semaglutide and tirzepatide to individuals with a BMI of 30+ or 27+ with health risks.
Experts Judith Korner and Sarah Adler say obesity is a chronic disease requiring treatment.
Online sales of these drugs raise safety concerns due to lack of regulation.
Weight-loss interest stems from societal pressures around food; taste changes may occur, with reduced intake.